Ali A, Elumalai T, Venkatesulu B, Hekman L, Mistry H, Sachdeva A
BMJ Oncol. 2025; 3(1):e000193.
PMID: 39886173
PMC: 11234997.
DOI: 10.1136/bmjonc-2023-000193.
Asafu Adjaye Frimpong G, Aboagye E, Owusu-Afriyie O, Owusu-Afriyie D, Antwi I, Akpaloo B
Cureus. 2024; 16(6):e62393.
PMID: 39006703
PMC: 11246774.
DOI: 10.7759/cureus.62393.
Wolpert J, Presson C, Kimball N, Lin B, Brandi L, Helo N
Investig Clin Urol. 2024; 65(4):334-341.
PMID: 38978213
PMC: 11231661.
DOI: 10.4111/icu.20240040.
Ogata Y, Akatsuka J, Endo Y, Mikami H, Yanagi M, Takeda H
BMC Urol. 2024; 24(1):108.
PMID: 38762458
PMC: 11102263.
DOI: 10.1186/s12894-024-01499-4.
Wang Z, Yin X, Yang P, Gong B, Liu H
Acta Biochim Biophys Sin (Shanghai). 2024; 56(5):675-687.
PMID: 38551020
PMC: 11177111.
DOI: 10.3724/abbs.2024001.
Apparent differences in prostate zones: susceptibility to prostate cancer, benign prostatic hyperplasia and prostatitis.
Yu X, Yan S, Liu R, Zhang Y
Int Urol Nephrol. 2024; 56(8):2451-2458.
PMID: 38528290
DOI: 10.1007/s11255-024-04012-w.
Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.
Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S
Int J Mol Sci. 2023; 24(14).
PMID: 37511400
PMC: 10380833.
DOI: 10.3390/ijms241411634.
Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs.
Sibona M, Destefanis P, Vercelli E, Secco S, Gontero P, Cindolo L
Prostate Cancer Prostatic Dis. 2023; 26(3):475-482.
PMID: 37500787
DOI: 10.1038/s41391-023-00686-y.
Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.
Yu X, Liu R, Song L, Gao W, Wang X, Zhang Y
Front Oncol. 2023; 13:1165732.
PMID: 37456243
PMC: 10348634.
DOI: 10.3389/fonc.2023.1165732.
Impact of Zone of Origin in Anterior Dominant Prostate Cancer: Long-Term Biochemical Recurrence-Free Survival in an Anatomically Well-Characterized Cohort.
Fine S, Al-Ahmadie H, Vertosick E, Vickers A, Chen Y, Gopalan A
Urol Pract. 2023; 9(5):459-465.
PMID: 37145713
PMC: 9988228.
DOI: 10.1097/UPJ.0000000000000322.
Association between prostate size and glandular tissue volume of the peripheral zone via novel combined MRI and histopathology: possible pathophysiological implications on prostate cancer development.
Lin B, Kim Cavdar I, Buxton M, Sellers J, Brandi L, Helo N
Int Urol Nephrol. 2023; 55(4):835-844.
PMID: 36739353
DOI: 10.1007/s11255-023-03483-7.
Landmarks in the evolution of prostate biopsy.
Connor M, Gorin M, Eldred-Evans D, Bass E, Desai A, Dudderidge T
Nat Rev Urol. 2023; 20(4):241-258.
PMID: 36653670
DOI: 10.1038/s41585-022-00684-0.
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Kumar R, Sena L, Denmeade S, Kachhap S
Nat Rev Urol. 2022; 20(5):265-278.
PMID: 36543976
PMC: 10164147.
DOI: 10.1038/s41585-022-00686-y.
METTL3 promotes prostatic hyperplasia by regulating PTEN expression in an mA-YTHDF2-dependent manner.
Li J, Yao H, Huang J, Li C, Zhang Y, Xu R
Cell Death Dis. 2022; 13(8):723.
PMID: 35985997
PMC: 9391461.
DOI: 10.1038/s41419-022-05162-4.
Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review.
Chopra H, Bibi S, Goyal R, Gautam R, Trivedi R, Upadhyay T
Front Oncol. 2022; 12:925379.
PMID: 35903701
PMC: 9315356.
DOI: 10.3389/fonc.2022.925379.
Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.
Gangavarapu K, Jowdy P, Foster B, Huss W
Am J Clin Exp Urol. 2022; 10(3):154-169.
PMID: 35874288
PMC: 9301063.
PD-L1 positive lympho-epithelial lesions in inflammatory prostate.
Dikov D, Koleva M, Simitchiev K, Baltov M, Sarafian V
Histol Histopathol. 2022; 37(8):749-755.
PMID: 35670049
DOI: 10.14670/HH-18-479.
An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine.
Bhat S, Rather S, Islam N
Asian J Urol. 2022; 9(2):109-118.
PMID: 35509487
PMC: 9051355.
DOI: 10.1016/j.ajur.2021.05.008.
Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer.
Sato S, Kimura T, Onuma H, Egawa S, Takahashi H
BJUI Compass. 2022; 2(3):169-177.
PMID: 35475132
PMC: 8988520.
DOI: 10.1002/bco2.47.
Prostate zones and cancer: lost in transition?.
Ali A, Du Feu A, Oliveira P, Choudhury A, Bristow R, Baena E
Nat Rev Urol. 2021; 19(2):101-115.
PMID: 34667303
DOI: 10.1038/s41585-021-00524-7.
